BOLT — Bolt Biotherapeutics Share News
0.000.00%
Last trade - 00:00- $12.08m
- -$5.52m
- $7.70m
Brief: Bolt Biotherapeutics Reports Q4 Results
Brief: Bolt Biotherapeutics To Present Preclinical Data For Bdc-3042, A Dectin-2-Targeting Agonistic Antibody, At 2023 Aacr Annual Meeting
Brief: Bolt Biotherapeutics Inc Says On December 14, Board Unanimously Voted To Increase The Number Of Directors On The Board From Nine To Ten
Brief: Bolt Biotherapeutics Appoints Laura Berner To Board Of Directors
Bolt Biotherapeutics Inc reports results for the quarter ended in September - Earnings Summary
Brief: Bolt Biotherapeutics Reports Third Quarter 2022 Financial Results And Provides Business Update
Bolt Biotherapeutics Inc expected to post a loss of 56 cents a share - Earnings Preview
Brief: Bolt Launches Checkout Links In Partnership With Revolve--Unifying Shoppers' Online And Offline Experiences And Shortening The Path To Purchase
U.S. RESEARCH ROUNDUP-Goodrx Holdings, Nextnav, Olo
U.S. STOCKS ON THE MOVE-Warby Parker, NV5 Global, Absci
U.S. STOCKS ON THE MOVE-Cyclacel, Major U.S. banks, Gold miners
U.S. STOCKS ON THE MOVE-Energy firms, WeWork, aTyr Pharma
SVB Securities downgrades Bolt Therapeutics on setback to cancer drug candidate
Brief: Bolt Biotherapeutics Inc - QTRLY Loss Per Share $0.61
Bolt Biotherapeutics Inc reports results for the quarter ended in June - Earnings Summary
Bolt Biotherapeutics Inc expected to post a loss of 68 cents a share - Earnings Preview
Several biotechs trading below cash position - Evercore ISI
Bolt Biotherapeutics Inc expected to post a loss of 72 cents a share - Earnings Preview
Brief: Bolt Biotherapeutics Files For Mixed Shelf Of Up To $250 Million